Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 4/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
| ▸ | KCNK18 | Q7Z418 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.38 |
| ▸ | CCR4 | P51679 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 3/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21226201 | 0.93 | ABCG2 (0.48) | ABCG2KCNK18AKR1C3AKR1C2KDR | |
| SCHEMBL29407530 | 0.93 | ABCG2 (0.48) | ABCG2KCNK18AKR1C3AKR1C2KDR | |
| SCHEMBL25450282 | 0.93 | KCNK18 (0.44) | ABCG2KCNK18AKR1C3AKR1C2CCR4 | |
| SCHEMBL29099907 | 0.92 | ABCG2 (0.47) | KIF11ABCG2KCNK18AKR1C3AKR1C2 | |
| SCHEMBL15449530 | 0.91 | KIF11 (0.38) | KIF11ABCG2KCNK18AKR1C3AKR1C2 | |
| SCHEMBL27181947 | 0.91 | KCNK18 (0.40) | KIF11ABCG2KCNK18AKR1C3AKR1C2 | |
| SCHEMBL7995293 | 0.89 | KCNK18 (0.39) | KIF11ABCG2KCNK18AKR1C3AKR1C2 | |
| SCHEMBL16428719 | 0.89 | ABCG2 (0.40) | KIF11ABCG2KCNK18AKR1C3AKR1C2 | |
| SCHEMBL1242289 | 0.84 | TRPV1 (0.50) | KIF11AKR1C3AKR1C2CHRM3 | |
| SCHEMBL31013596 | 0.84 | HSD17B2 (0.44) | KIF11ABCG2AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7250519-B2 | Method for the production of arylamines | MERCK PATENT GMBH (DE) | 2007-07-31 | — | — | US | disclosed |
| EP-1442007-B1 | METHOD FOR THE PRODUCTION OF ARYLAMINES | MERCK PATENT GMBH (DE) | 2006-11-29 | — | — | EP | disclosed |
| US-20050054854-A1 | Method for the production of arylamines | MERCK PATENT GMBH (DE) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054854-A1 | Method for the production of arylamines | DDT, PDS5A, KMO | KIF11 3269/4885ABCG2 1877/4885KCNK18 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.